Why the study?
Does perioperative beta-blockade reduce cardiovascular events or increase mortality and stroke in patients with atherosclerotic disease undergoing noncardiac surgery?
Population
8351 patients with established or presumed atherosclerotic disease undergoing noncardiac surgery
Comparison
Perioperative beta-blockade vs Untreated controls
Design
Editorial
Follow-up
30 days
Authors
Loading...
This editorial argues that while the POISE trial demonstrated increased mortality and stroke with high-dose perioperative beta-blockade, individualized, lower-dose, and carefully monitored beta-blocker therapy may still be beneficial and appropriate for surgical patients with ischemic heart disease.
Does perioperative beta-blockade reduce cardiovascular events or increase mortality and stroke in patients with atherosclerotic disease undergoing noncardiac surgery?
This editorial argues that while the POISE trial demonstrated increased mortality and stroke with high-dose perioperative beta-blockade, individualized, lower-dose, and carefully monitored beta-blocker therapy may still be beneficial and appropriate for surgical patients with ischemic heart disease.
Stone et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: